5 results about "Abacavir" patented technology

The application discloses a preparation method of an abacavir metabolite, and belongs to the field of drug metabolite synthesis. The whole process is reasonable in design, strong in operability, and has high implementation value and social and economic benefits. The method uses compound I as a starting material, and synthesizes the abacavir metabolite through two-step reactions. The optimal synthesis step and reaction condition are screened through experiments. The abacavir metabolite synthesized by the method has a liquid-phase purity of 98.2% or above and a chiral purity of 99.9% or above, provides a test sample for abacavir research, and has important research reference value in clinical pharmacokinetic research and new drug research and development.

The present invention discloses a pharmaceutical composition containing homoharringtonine and its application in the preparation of anti-HIV viral drugs. The pharmaceutical composition is composed of homoharringtonine and a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor. The nucleoside reverse transcriptase inhibitor is selected from one of the compounds zidovudine, lamivudine, and abacavir, and the non-nucleoside reverse transcriptase inhibitor is selected from one of the compounds nevirapine, efavirenz, and rilpivirine. The pharmaceutical composition has a significant synergistic effect in treating HIV, improves the efficacy of the drug, reduces the dosage of a single drug, reduces toxic side effects, and can significantly inhibit the production of viruses in combination, producing a very significant antiviral effect, and improving the current status of the treatment of HIV-1, especially middle and late stage AIDS.

The invention relates to application of abacavir in preparation of a medicine for treating rheumatoid arthritis, and belongs to the technical field of biological medicine. The abacavir is found to be capable of relieving related symptoms of rheumatoid arthritis for the first time, and particularly, abacavir is proved to be capable of inhibiting joint swelling and bone erosion of mice and relieving pathological phenotypes in a collagen-induced arthritis mouse model; meanwhile, in a peripheral blood mononuclear cell (PBMCs) sample of a patient with rheumatoid arthritis, abacavir is found to be capable of reducing expression of interferon stimulated gene (ISGs) family related genes, so that abacavir can be used as a novel therapeutic drug for rheumatoid arthritis. In conclusion, abacavir can be used as a medicine for treating rheumatoid arthritis and has very high clinical application value.

The application discloses an abacavir degrading bacterium. The degrading bacterium is obtained from activated sludge in an aerobic tank of a sewage treatment plant in Guangzhou, Guangdong, and is obtained through artificial domestication culture and separation and purification. The name of the bacterium is Pseudomonas sp. abacavir-1, and the bacterium is preserved in the Guangdong Microbial Culture Collection Center of the Guangdong Institute of Microbiology, located at No. 59, Building 5, Guangzhou Martyrs' Road, Guangzhou, on September 23, 2022, and the preservation number is GDMCC NO: 62829. The strain of the application has the ability to degrade single abacavir under oligotrophic conditions, can be used for degrading abacavir in the environment or a sewage treatment plant, and provides a new germplasm resource for abacavir treatment.

The application relates to application of abacavir in preparation of a drug for treating rheumatoid arthritis, and belongs to the technical field of biological medicine. It is found for the first time that abacavir can relieve the related symptoms of rheumatoid arthritis, and specifically, it is proved in a collagen-induced arthritis mouse model that abacavir can inhibit joint swelling and bone erosion of the mouse, and relieve the pathological phenotype; meanwhile, it is found in peripheral blood mononuclear cell (PBMCs) samples of rheumatoid arthritis patients that the use of abacavir can reduce the expression of interferon stimulated gene (ISG) family related genes, which indicates that the abacavir can be used as a new type of drug for treating rheumatoid arthritis. In summary, the abacavir can be used as a drug for treating rheumatoid arthritis, and has high clinical application value.